All In Biotech

Drug Trial Radar · NCT06741228

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 214 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

214

Actual

Start

Dec 11, 2024

Primary completion

Jul 15, 2026

Study completion Apr 2027

Sponsor

Lead sponsor
Definium Therapeutics US, Inc.Industry
Sponsor type
Industry
First posted
Dec 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage

Conditions

  • Generalized Anxiety Disorder

Interventions

  • PlaceboOther

    A substance that is designed to have no therapeutic value

  • DT120Drug

    A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12Time frame: Baseline to Week 12

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Lighthouse Psychiatry

    Gilbert, Arizona

  • Scottsdale Research Institute

    Scottsdale, Arizona

  • Kadima Neuropsychiatry Institute

    La Jolla, California

  • UCSF Department of Neurology

    San Francisco, California

  • Psychedelic Science Institute

    Santa Monica, California

  • Mountain View

    Denver, Colorado

  • Clinical Neuroscience Solutions Inc.

    Jacksonville, Florida

  • Segal Trials

    Lauderhill, Florida

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • iResearch Atlanta

    Decatur, Georgia

  • CenExel iResearch, LLC

    Savannah, Georgia

  • Uptown Research Institute

    Chicago, Illinois

  • Adams Clinical Boston

    Boston, Massachusetts

  • Adams Clinical Watertown

    Watertown, Massachusetts

  • Hassman Research Institute

    Marlton, New Jersey

  • Spectrum Neuroscience and Treatment Institute

    New York, New York

  • Adams Clinical Harlem

    New York, New York

  • New York State Psychiatric Institute (NYSPI)

    New York, New York

  • Adams Clinical Bronx

    The Bronx, New York

  • Cleveland Clinic Lutheran Hospital

    Cleveland, Ohio

  • Summit Headlands LLC

    Portland, Oregon

  • Scranton Medical Institute

    Moosic, Pennsylvania

  • Adams Clinical Philadelphia

    Philadelphia, Pennsylvania

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • Clinical Neuroscience Solutions, Inc.

    Memphis, Tennessee

  • University of Texas at Austin

    Austin, Texas

  • Austin Clinical Trial Partners

    Austin, Texas

  • BioBehavioral Research of Austin

    Austin, Texas

  • FutureSearch Trials of Dallas, LLC

    Dallas, Texas

  • Adams Clinical Dallas

    DeSoto, Texas

  • Cedar Clinical Research

    Draper, Utah

  • Inner Space Research

    Orem, Utah

  • Memory Clinic Inc.

    Bennington, Vermont

  • Seattle Neuropsychiatric Treatment Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.